UBM announces rescheduled Japan pharma and bio events

Now to be held in pharma heartland of Osaka in July

Leading events organiser UBM Live has announced that, following the postponement of its CPhI, ICSE, P-MEC and BioPh Japan events in Tokyo as a result of the recent earthquake in northern Japan, the events have now been rescheduled and will be held from 13 - 15 July 2011 at the Intex Osaka Exhibition Centre.

The Japanese business community is intent on picking itself up as quickly as possible from the effects of the disaster and there is a strong feeling of the need to get back to business as usual. UBM expects that the Osaka events will attract more than 150 exhibitors and around 8,000 visitors.

In addition to being Japan's second largest city, Osaka is the centre of the Kansai area, one of the main regions in Japan for pharmaceutical r&d and manufacturing, with numerous Japanese and multinational pharmaceutical companies having their head office, factories and r&d centres located there and in surrounding cities. The events are conveniently located for visitors from prefectures in the Kansai region such as Osaka, Hyogo, Kyoto, Tokushima and Shiga, as well as other key pharmaceutical manufacturing prefectures with easy access to Osaka such as Toyama, Shizuoka, Aichi, Gifu and Yamaguchi.

‘Following our initial announcement regarding the unfortunate postponement of the events in Tokyo, we received many requests from exhibitors asking if there was some way that we could facilitate an opportunity for them to meet their clients in Japan this year,’ commented Annemieke Timmers, CPhI Brand Director.

‘We also received unanimous feedback from our Japanese customers and we recognise that it is precisely at times such as this that CPhI Japan, along with ICSE, P-MEC and BioPh Japan, could help contribute towards the stable supply of pharmaceutical products in what is the second largest pharma market after the US.’

‘After careful consideration, we decided that it was important to reschedule the events in 2011 to provide the Japanese market with a recognised, industry-leading platform for networking and learning by bringing together representatives of the international pharma community in one location, allowing them to do business, meet with existing clients and new prospects, as well as stay informed of developments in the industry,’ added Haf Cennydd, Brand Director ICSE, P-MEC and BioPh.

‘We are currently putting together a schedule of conference sessions that will run alongside the events over the three-day period. These will cover a wide variety of topics relevant to each of the co-located shows that will enhance the educational experience for exhibitors and visitors alike.’

Further information on CPhI, ICSE, P-MEC and BioPh Japan can be found at www.cphijapan.com.

Companies